The ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA) brings together professionals from various expertise dedicated to advancing the use of bacteriophages and other new non-traditional therapeutic approaches to treat infectious diseases. Their mission includes:
Impact of phage therapy in post-weaning piglets challenged with ETEC strain in a controlled minitrial.
Mahmud MR, Uddin MK, Kareljärvi P, Jalasvuori M, Peräkylä J, Eklund T, Biström M, Hasan S, Vatanen T, Kiljunen S, Oliviero C. Porcine Health Manag. 2026 Apr 29;12(1):36.
Integrated wet lab and in silico discovery and characterization of bacteriophages with antibiotic synergy against multidrug resistant Acinetobacter baumannii.
Nicolosi A, Bonanno Ferraro G, Brandtner D, Veneri C, Artuso I, Marchetti M, La Rosa G, Stefani S, Stracquadanio S. Sci Rep. 2026 Mar 26;16(1):15091
Antibacterial potential of five phages in controlling Enterococcus faecalis and Enterococcus faecium.
Tuomala H, Nylund T, Mustonen M, Flod A, Kiljunen S. Virol J. 2026 Jun 2;23(1):143.
Mucin modulates phage infection dynamics and biofilm formation in enteropathogenic Yersinia enterocolitica.
Goladze S, de Oliveira Patricio D, Allen E, Penttinen R, Tuomala H, Patpatia S, Ylänne M, Petersen B, Skurnik M, Almeida GMF, Sundberg LR. Curr Res Microb Sci. 2026 Jun 3;11:100618
Rethinking informed consent in phage therapy: why location and approach matter.
Nir-Paz R, Pirnay JP, Ferry T, Drulis-Kawa Z, Classen AY, Scobie A, Lester R, Katvan E, Hafkemeyer S, McCallin S, Suh GA. Clin Microbiol Infect. 2026 Apr 10:S1198-743X(26)00191-6
Cross-border dialogue: An international survey of regulators on phage therapy.
Alvarez RD, Årdal C, Classen AY, Nagel TE, Ceyssens PJ, German GJ. Int J Antimicrob Agents. 2025 Dec;66(6):107614
Phage therapy.
Mikael Skurnik, Sivan Alkalay-Oren, Maarten Boon, Martha Clokie, Thomas Sicheritz-Pontén,Krystyna Dąbrowska, Graham F. Hatfull, Ronen Hazan, Matti Jalasvuori, Saija Kiljunen, Rob Lavigne, Danish J. Malik, Ran Nir-Paz & Jean-Paul Pirnay. Nature Reviews Methods Primers 2025. 5, Article number: 10
2025 ICM: Role of Unconventional Medications.
Suh GA; ESGNTA; Scobie A; ESGNTA; Piuzzi NS, Bartak V, Anyaehie UE, Arciola CR, Batailler C, Benes M, Binlaksar R, Buttaro M, Damioli LE, de Beaubien BC, Dietz MJ, Doub JB, Elmenawi KA, Falez F, Ferry T; ESGNTA; Goswami K, Kucukdurmaz F, Li B, Metsemakers WJ, Moriarty TF, Saeed M, Shah RP, Springer B, Tootsi K, Tsiridis E, Urish KL. J Arthroplasty. 2025 Oct 31:S0883-5403(25)01395-6
Phages and phage-borne enzymes as new antibacterial agents.
McCallin S, Drulis-Kawa Z, Ferry T, Pirnay JP, Nir-Paz R. Clin Microbiol Infect. 2023;20:S1198-743X(23)00528-1.
Personalized Phage Therapy: Basic Principles of monitoring and treatment: Supplement 5 1 Nov 2023
Nir-Paz R, Iredell J, Suh G, Fabijan AP. Clinical Infectious Diseases, Vol 77, Issue Supplement 5, 1 November 2023.
Phage therapy for recurrent MDR Pseudomonas infections in the setting of neurogenic bladder and reflux:
assistance with assessing candidacy and treatment protocol
13 Apirl 2026, 14:00 CEST
Safety and Feasibility of a National Phage Therapy Program in Australia
07 Apirl 2026, 23:00 CEST
If you have questions or comments for our study group, we warmly invite you to contact us!
